Trials / Terminated
TerminatedNCT00359476
A Study of Vinflunine in Patients With Gastric Cancer
A Multicenter, Single-Arm, Phase II Study of Single-Agent Vinflunine in the Second-line Treatment of Patients With Gastric Cancer
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn if vinflunine can shrink or slow the growth of cancer in patients with advanced or metastatic stomach cancer who have progressed on a prior treatment with a fluoropyrimidine or taxane-containing chemotherapy regimen. The safety of this treatment will also be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vinflunine | solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2007-10-01
- Completion
- 2007-11-01
- First posted
- 2006-08-02
- Last updated
- 2010-03-02
Locations
6 sites across 3 countries: Malaysia, Philippines, South Korea
Source: ClinicalTrials.gov record NCT00359476. Inclusion in this directory is not an endorsement.